Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer

Overview

Journal Cancer Discov

Specialty Oncology

Date 2017 Dec 7

PMID 29208774

Citations 13

Authors

Inaki Comino-Mendez

Nicholas Turner

Affiliations

Soon will be listed here.

Abstract

<b/> Advances in circulating tumor DNA (ctDNA) analysis are revealing new treatment strategies for patients with cancer. Detection of residual disease with ctDNA analysis predicts relapse with high accuracy after treatment for early-stage lung cancer. .

Citing Articles

Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma.

Budeyri I, Guckelberger O, Oppermann E, Roy D, Sliwinski S, Becker F Cells. 2025; 14(1.

PMID: 39791707 PMC: 11720075. DOI: 10.3390/cells14010006.

Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article.

Dong Q, Chen C, Hu Y, Zhang W, Yang X, Qi Y Cancer Biol Ther. 2023; 24(1):2274123.

PMID: 37955635 PMC: 10653633. DOI: 10.1080/15384047.2023.2274123.

Circulating Tumor Cells as a Promising Tool for Early Detection of Hepatocellular Carcinoma.

Salehi M, Lavasani Z, Keshavarz Alikhani H, Shokouhian B, Hassan M, Najimi M Cells. 2023; 12(18).

PMID: 37759483 PMC: 10527869. DOI: 10.3390/cells12182260.

Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review.

Di Sario G, Rossella V, Famulari E, Maurizio A, Lazarevic D, Giannese F Front Genet. 2023; 14:1152470.

PMID: 37077538 PMC: 10109350. DOI: 10.3389/fgene.2023.1152470.

Detection of Polysomy by Next-generation Sequencing and Its Clinical Relevance for Inhibitors.

Sun B, Qiu T, Zeng X, Duan J, Bai H, Xu J Cancer Res Commun. 2023; 3(4):532-539.

PMID: 37025355 PMC: 10072163. DOI: 10.1158/2767-9764.CRC-22-0438.